Background. It has been suggested that endothelium-related vasomotion is important in the control of coronary circulation. Our goal was to determine if endothelium-dependent dilation of the coronary vasculature was altered with aging in 18 patients with atypical chest pain (age, 23-70 years) who had
Age is a risk factor for cardiovascular disease. 1 Aging is associated with morphological and functional changes in the coronary vasculature. It has been shown that aging decreases capillary density and increases collagen content in the arteriolar wall.2 In addition, aging decreases coronary flow reserve, predominantly in subendocardial myocardium in animals, 3'4 indicating that myocardial perfusion decreases with aging. In the resistance artery of rats, endotheliumdependent dilation decreases with age.5 '6 Recent clinical studies7'8 have demonstrated that dilation of large epicardial coronary artery evoked with intracoronary administration of acetylcholine decreases or disappears with aging in patients with angiographically normal coronary arteries, suggesting that aging impairs endothelium-dependent dilation of large epi-cardial coronary arteries. However, no study has examined the effects of aging on endothelium-dependent vasodilation of resistance coronary artery in humans. It is well recognized that endothelium plays an important role in the control of coronary blood flow by regulating coronary vascular resistance.9 10 Our goal was to determine if endothelium-dependent vasodilation of resistance coronary artery evoked with acetylcholine is altered by aging in humans.
Methods

Study Patients
Eighteen patients who had atypical chest pain, normal exercise test results, and angiographically normal coronary arteries were studied. Patients who had arterial hypertension or evidence of left ventricular hypertrophy as assessed by ECG and echocardiography and were receiving an antihypertensive or a cholesterollowering drug were excluded. Patients who had hypercholesterolemia (total cholesterol, >220 mg/dL), diabetes mellitus, cardiomyopathy, valvular heart disease, and left or right bundle branch block on the ECG were excluded. Patients with variant angina who had angiographically documented coronary spasm also were excluded.
The research proposal of this study was approved by the institutional review committee for clinical research.
Written informed consent was obtained from each patient after the study protocol was explained.
Quantitative Coronary Arteriography
Coronary cineangiograms were recorded on 35-mm cinefilm (60 frames per second) using a Siemens cineangiographic system. A view was selected that allowed the best visualization of the left anterior descending coronary artery (the study artery).
We determined changes in the luminal diameter at the proximal segments of the left anterior descending coronary artery, a segment 2 to 3 mm distal to the tip of the Doppler catheter, as we described previously.11,12 An end-diastolic frame was selected on a cineprojector, and the arterial segments under study were scanned with a videocamera. The images were digitized and analyzed with a videodensitometric analysis system (Kontron Instruments, Germany). 13 The increases in coronary blood flow evoked by acetylcholine were estimated from the product of the mean coronary blood flow velocity and the cross-sectional area of the proximal arterial segment at the tip of the Doppler catheter, and increases were expressed as percent increases from the baseline level. The increases in coronary blood flow in response to papaverine were assessed from the product of mean blood flow velocity and the baseline coronary cross-sectional area, assuming that the cross-sectional area changed little as a result of administration of papaverine. We did not measure the arterial crosssectional area after papaverine administration because peak flow velocity after papaverine usually occurred at 20 to 40 s after the drug injection, so it was difficult to record simultaneously peak flow velocity and arterial cross-sectional area in such a brief period of time. We previously examined the effects of the administration of 10 mg papaverine i.c. on the coronary artery diameter in a group of 28 receiving antianginal drugs, and five patients were receiving calcium channel blockers and nitrates. These drugs were discontinued at least 24 h before the study.
After completion of the diagnostic catheterization, the following interventions were performed: 1) a bolus injection of papaverine (10 mg/5 mL) through the guiding catheter; 2) infusion of saline (0.5 mL/min for 2 minutes) through the Doppler catheter; and 3) infusions of acetylcholine (0.5 mL/min) at the doses of 1, 3, 10, and 30 ,g/min (for 2 minutes at each dose) through the Doppler catheter. We confirmed that acetylcholine at the dosage of 30 ,g/min caused the maximum increase in coronary blood flow, because infusion of acetylcholine at the dose of 60 ,ug/min did not further increase coronary blood flow velocity in all patients. It has been demonstrated that papaverine (10 mg) injected into the left main coronary artery evokes the maximal increase in coronary blood flow velocity with no changes in arterial pressure and heart rate.13 '14 After completion of the study with one drug, we waited for at least 5 minutes before beginning infusion of the next drug. Coronary arteriography was performed before and 2 minutes after each dose of acetylcholine. Mean and phasic coronary blood flow velocities, arterial blood pressure, and heart rate were monitored continuously and recorded on a recorder (Nihon-Kohden polygraph system, Tokyo). Values during a steady-state condition were used for later analysis.
Drugs
Acetylcholine chloride (Dai-ichi Pharmaceutical Co., Tokyo) and papaverine (Dai-Nippon Pharmaceutical Co., Tokyo) were used.
Statistical Analysis
Data are expressed as mean+SD. The relationship between various hemodynamic variables such as coronary blood flow and age was assessed by a linear regression analysis. To characterize the blood flow response to acetylcholine, the slope of the percent increase in coronary blood flow in response to acetylcholine (y axis, percent increase in blood flow; x axis, log[doses (,gg/min) of acetylcholine]) was determined using a linear regression analysis by plotting the blood flow response against four doses of acetylcholine in each patient. Correlation coefficient ranged from .75 to .99 (mean±SD, .89±.11).
When serial changes in arterial pressure, heart rate, arterial diameter, and coronary blood flow were compared, ANOVA for repeated measures where y is the percent change in the diameter, and x is age (years). There was no correlation between ages and the diameter responses to acetylcholine at the dosage of 30 ,ug/min (P=-.137).
Acetylcholine increased estimated coronary blood flow in a dose-dependent manner (increase: 46±45%, 132±82%, 269+118%, and 363±111% at dosages of 1, 3, 10, and 30 ,ug/min, respectively). The maximum blood flow response occurred in two patients at dosages of 10 ,g/min and in 16 patients at the dosage of 30 ,ug/min. Peak coronary blood flow response to acetylcholine and coronary blood flow response to papaverine in each patient are shown in Table 2 . As shown in Fig 1A, the peak increase in coronary blood flow with acetylcholine varied widely among patients (from 220% to 560%) and correlated significantly (r= -.86, P<.001) with age, whereas there was a trend of decrease in the coronary blood flow response to papaverine with aging (r= -.44, P=.07). We compared the percentage of the peak coronary blood flow response to acetylcholine with that to papaverine in each patient to assess the effect of aging on endotheliumdependent control of coronary blood flow. The percentage of the response decreased significantly with age ( Fig   1B) . The slope of the blood flow relation to acetylcholine (y axis, percent increase in coronary blood flow; x axis, log[doses of acetylcholine]) also correlated significantly with age (r=-.78, P<.001) (Fig 2) .
Discussion
The major new finding of this study is that the coronary blood flow response to acetylcholine (an endotheliumdependent vasodilator) decreased significantly with aging, whereas the blood flow response to papaverine (an endo- 10 ,ug/min) correlated inversely with aging but that the response to the high dose (30 ,ug/min) of acetylcholine did not. The endothelium-dependent vasodilating response of the epicardial coronary arteries to acetylcholine is a composite of receptor-mediated and flow-related stimulation.9'10,1420 Therefore, the diminished vasodilation in 29 We did not measure changes in arterial cross-sectional area of the large epicardial coronary vessels after papaverine (see "Methods"), which results in underestimation of the coronary blood flow response to papaverine. It is unlikely that this limitation is critical because vasodilation of the large epicardial vessels in response to papaverine does not correlate with aging (authors' unpublished observation).
We did not explore mechanisms of the attenuated coronary blood flow response to acetylcholine in this study, but they may relate to age-related decrease in release of endothelium-dependent relaxing factors, inactivation of endothelium-dependent relaxing factors, or concomitant release of constricting factors by microvascular endothelial cells. Kuo et a130 recently demonstrated that impaired endothelium-dependent dilation of coronary microvessels in atherosclerotic animals was restored by administration of l-arginine (a precursor of endothelium-dependent relaxing factors3l'32), suggesting the important role of endothelium-dependent relaxing factors in control of coronary blood flow in atherosclerosis. Future studies are needed to determine the role of age-related endothelial dysfunction in the coronary microcirculation.
Conclusions Endothelium-derived vasoactive substances such as nitric oxide play an important part in myocardial perfusion.910,33 This study indicates that endothelium-dependent vasodilation of the coronary vasculature evoked by acetylcholine may be impaired with increasing age in humans, which may contribute to altered myocardial perfusion and the manifestation of coronary artery disease in patients with advanced age. Age-related endothelial dysfunction may contribute to the development of coronary artery disease in humans.
